Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction

This publication has 30 references indexed in Scilit:

• Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months
  The Lancet, 1994
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Platelet activation during coronary angioplasty in humans.
  Circulation, 1993
• Circulating aggregated platelets, number of platelets per aggregate, and platelet size during acute myocardial infarction
  The American Journal of Cardiology, 1992
• The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
  Journal of the American College of Cardiology, 1991
• Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group.
  Circulation, 1990
• Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial infarction
  Journal of the American College of Cardiology, 1989
• Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction.
  Heart, 1988
• Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
  Journal of the American College of Cardiology, 1988
• Detection of platelet deposition at the site of peripheral balloon angioplasty using indium-111 platelet scintigraphy
  The American Journal of Cardiology, 1985